CONTROL BIONICS LIMITED — Capital/Financing Update 2026

Jan 28, 2026

==> picture [145 x 45] intentionally omitted <==

29 January 2026

Control Bionics Signs US Distribution Agreement with PRC-Saltillo for the NeuroNode®

Control Bionics Limited (ASX: CBL) is pleased to announce that it has signed a distribution agreement with PRC-Saltillo (PRC), a world leader in Augmentative and Alternative Communication (AAC) solutions, for the distribution of Control Bionics’ NeuroNode® technology in the United States.

Under the agreement, PRC will act as a distributor of the NeuroNode in the US market , expanding access to Control Bionics’ surface electromyography (sEMG)–based access technology for individuals with complex communication needs. Whilst the commercial terms of the agreement are confidential the agreement has an initial 2-year term.

PRC has had access to the NeuroNode throughout 2025, during which time a number of PRC sales staff have already been trained on the technology. NeuroNode devices have been with the PRC team for trials and demonstrations, and insurance funding has already been approved for PRC clients to access the NeuroNode .

The NeuroNode is designed to complement PRC’s existing AAC solutions by providing an additional access method for users who may have difficulty with traditional access technologies. By detecting very small muscle activations, the NeuroNode enables individuals to control communication devices and other technology where alternative access methods may not be viable.

PRC is widely recognised as a global leader in the AAC market , with a long history of delivering innovative communication solutions and clinical support to individuals with communication disabilities. Control Bionics, meanwhile, has more than 20 years’ experience in the development and commercialisation of sEMG-based assistive technology.

Control Bionics CEO, Jeremy Steele , said:

“PRC is a world leader in AAC solutions, and we are very pleased to formalise this distribution agreement for the NeuroNode in the United States. PRC has been working with the NeuroNode throughout 2025, with trained sales staff, devices in market for demonstrations, and funding already approved for clients, which gives us confidence in their ability to scale access to the technology.

While we expect sales to ramp up gradually as partners onboard, continue to train teams and integrate the product into their sales channels, the agreement provides a strong foundation for sustainable growth in the US market.

This agreement represents an important step in expanding NeuroNode availability in the US and reinforces the growing recognition of sEMG-based access as a valuable complement to existing AAC solutions.

The agreement is also a further demonstration of one of Control Bionics’ five key strategic priorities of expanding NeuroNode sales across key regions with key strategic distribution relationships, adding to our recently announced distribution partnership with Tobii Dynavox.”

Control Bionics Limited

Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Victoria, 3121, Australia T: +61 3 9897 3576 W: www.controlbionics.com ABN: 45 115 465 462

This ASX announcement has been approved for release by the CEO of Control Bionics Limited.

For further information, please contact:

Investors and Media:

Jeremy Steele – CEO and Managing Director jsteele@controlbionics.com

Brett Crowley - Company Secretary brettcrowley@controlbionics.com For further information visit the website: https://www.controlbionics.com/

About Control Bionics:

Control Bionics is a medical device company that has more than 20 years’ experience in the development and use of surface Electromyography (EMG) devices.

About NeuroNode:

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

About NeuroStrip:

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.

Control Bionics Limited Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Victoria, 3121, Australia T: +61 3 9897 3576 W: www.controlbionics.com ABN: 45 115 465 462